T-cell Prolymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for T-cell Prolymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors [Phase 1]
Phase 1 trial of KT-333 in adults with refractory lymphomas and solid tumors reports safety, pharmacokinetics, pharmacodynamics, and prelimi…
-
CLINICAL_TRIALS trial_result · 2024-12-12Clinical Trial Update: Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia [Phase 1]
Phase 1 trial of fludarabine, cytarabine, and pegcrisantaspase for relapsed or refractory leukemias was terminated; the update notes the stu…
-
CLINICAL_TRIALS trial_result · 2024-10-10Clinical Trial Update: Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia [Phase 1]
Phase 1 study evaluating itacitinib with alemtuzumab in recurrent T-cell prolymphocytic leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2024-07-18Clinical Trial Update: Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab [Phase 2]
Phase 2 trial evaluating letermovir for prevention of cytomegalovirus reactivation in patients with hematologic malignancies treated with al…
-
CLINICAL_TRIALS trial_result · 2022-12-19Clinical Trial Update: A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia [Phase 2]
Phase 2 trial evaluating venetoclax plus ibrutinib in T-cell prolymphocytic leukemia has completed with results posted in 2022.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-04-29Clinical Trial Update: Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) [Phase 1]
Phase 1 trial evaluating subcutaneous recombinant human IL-15 in combination with alemtuzumab for refractory or relapsed adult T-cell leukem…
-
CLINICAL_TRIALS trial_result · 2022-01-05Clinical Trial Update: Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL) [Phase 2]
Phase 2 trial update evaluating combined immunochemotherapy in patients with T-cell prolymphocytic leukemia (T-PLL) has been completed.
-
CLINICAL_TRIALS trial_result · 2019-05-29Clinical Trial Update: Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 clinical trial evaluating autologous peripheral blood stem cell transplant followed by donor bone marrow transplant in high-risk B- …
-
CLINICAL_TRIALS trial_result · 2017-12-08Clinical Trial Update: Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia [Phase 2]
Phase 2 trial evaluating fludarabine phosphate with total-body irradiation as conditioning before donor peripheral blood stem cell transplan…
-
CLINICAL_TRIALS trial_result · 2017-12-07Clinical Trial Update: Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating autologous stem cell transplant followed by donor stem cell transplant in relapsed or refractory lymphom…
-
CLINICAL_TRIALS trial_result · 2016-12-06Clinical Trial Update: CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial update evaluating CAR-pNK cell immunotherapy for CD7-positive leukemias and lymphomas. The available snippet does n…
-
CLINICAL_TRIALS trial_result · 2013-07-25Clinical Trial Update: A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) [Phase 1]
Phase 1 clinical trial update for niraparib (MK-4827) in participants with advanced solid tumors or hematologic malignancies, sponsored by T…